Brashear, A. et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 130, 828-835

Department of Neurology, Wake Forest University, Winston Salem, NC 27157, USA.
Brain (Impact Factor: 9.2). 04/2007; 130(Pt 3):828-35. DOI: 10.1093/brain/awl340
Source: PubMed


Rapid-onset dystonia-parkinsonism (RDP) (also known as DYT12) is characterized by the abrupt onset of dystonia and parkinsonism and is caused by mutations in the ATP1A3 gene. We obtained clinical data and sequenced the ATP1A3 gene in 49 subjects from 21 families referred with 'possible' RDP, and performed a genotype-phenotype analysis. Of the new families referred for study only 3 of 14 families (21%) demonstrated a mutation in the ATP1A3 gene, but no new mutations were identified beyond our earlier report of 6. Adding these to previously reported families, we found mutations in 36 individuals from 10 families including 4 de novo mutations and excluded mutations in 13 individuals from 11 families. The phenotype in mutation positive patients included abrupt onset of dystonia with features of parkinsonism, a rostrocaudal gradient, and prominent bulbar findings. Other features found in some mutation carriers included common reports of triggers, minimal or no tremor at onset, occasional mild limb dystonia before the primary onset, lack of response to dopaminergic medications, rare abrupt worsening of symptoms later in life, stabilization of symptoms within a month and minimal improvement overall. In comparing ATP1A3 mutation positive and negative patients, we found that tremor at onset of symptoms, a reversed rostrocaudal gradient, and significant limb pain exclude a diagnosis of RDP. A positive family history is not required. Genetic testing for the ATP1A3 gene is recommended when abrupt onset, rostrocaudal gradient and prominent bulbar findings are present.

Download full-text


Available from: Marina A J Tijssen, Oct 10, 2015
41 Reads
  • Source
    • "Unaffected carriers have been reported for other ATP1A3 missense mutations in rapid-onset dystonia-parkinsonism [18,19,27], but there is no evidence for incomplete penetrance in CAPOS syndrome. We demonstrated a de novo origin for the ATP1A3 c.2452G > A mutation in Family 1 (Figure 1B), and the clinical and family histories are most compatible with separate, recurrent de novo mutations in Families 2 and 3 as well. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We undertook genetic analysis of three affected families to identify the cause of dominantly-inherited CAPOS (cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss) syndrome. We used whole-exome sequencing to analyze two families affected with CAPOS syndrome, including the original family reported in 1996, and Sanger sequencing to assess familial segregation of rare variants identified in the probands and in a third, apparently unrelated family with CAPOS syndrome. We found an identical heterozygous missense mutation, c.2452G > A (p.(Glu818Lys)), in the Na+/K+ ATPase alpha3 (ATP1A3) gene in the proband and his affected sister and mother, but not in either unaffected maternal grandparent, in the first family. The same mutation was also identified in the proband and three other affected members of the second family and in all three affected members of the third family. This mutation was not found in more than 3600 chromosomes from unaffected individuals. Other mutations in ATP1A3 have previously been demonstrated to cause rapid-onset dystonia-parkinsonism (also called dystonia-12) or alternating hemiplegia of childhood. This study shows that an allelic mutation in ATP1A3 produces CAPOS syndrome.
    Orphanet Journal of Rare Diseases 01/2014; 9(1):15. DOI:10.1186/1750-1172-9-15 · 3.36 Impact Factor
  • Source
    • "Missense mutations in ATP1A3 were previously identified as the primary cause of rapid-onset dystonia-parkinsonism (RDP; DYT12), a disorder characterised by abrupt onset of the permanent symptoms of dystonia with parkinsonism, often after a stressful event, typically in late adolescence or early adulthood [10], [11]. No mutations identified to date are shared between the two disorders, but three AHC-causing mutations affect amino acid positions also affected by RDP mutations (I274N/T, D801N/Y, D923Y/N). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Missense mutations in ATP1A3 encoding Na(+),K(+)-ATPase α3 have been identified as the primary cause of alternating hemiplegia of childhood (AHC), a motor disorder with onset typically before the age of 6 months. Affected children tend to be of short stature and can also have epilepsy, ataxia and learning disability. The Na(+),K(+)-ATPase has a well-known role in maintaining electrochemical gradients across cell membranes, but our understanding of how the mutations cause AHC is limited. Myshkin mutant mice carry an amino acid change (I810N) that affects the same position in Na(+),K(+)-ATPase α3 as I810S found in AHC. Using molecular modelling, we show that the Myshkin and AHC mutations display similarly severe structural impacts on Na(+),K(+)-ATPase α3, including upon the K(+) pore and predicted K(+) binding sites. Behavioural analysis of Myshkin mice revealed phenotypic abnormalities similar to symptoms of AHC, including motor dysfunction and cognitive impairment. 2-DG imaging of Myshkin mice identified compromised thalamocortical functioning that includes a deficit in frontal cortex functioning (hypofrontality), directly mirroring that reported in AHC, along with reduced thalamocortical functional connectivity. Our results thus provide validation for missense mutations in Na(+),K(+)-ATPase α3 as a cause of AHC, and highlight Myshkin mice as a starting point for the exploration of disease mechanisms and novel treatments in AHC.
    PLoS ONE 03/2013; 8(3):e60141. DOI:10.1371/journal.pone.0060141 · 3.23 Impact Factor
  • Source
    • "DYT16 cases that present with pure dystonia are an important differential diagnosis of DYT1 and DYT6 dystonia [38]. There are many similarities between DYT16 and DYT12, such as prominent bulbar signs and rostro-caudal gradient; however, DYT12 has an abrupt onset and a clear autosomal dominant mode of inheritance [39]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The majority of studies investigating the molecular pathogenesis and cell biology underlying dystonia have been performed in individuals with primary dystonia. This includes monogenic forms such as DYT1and DYT6 dystonia, and primary focal dystonia which is likely to be multifactorial in origin. In recent years there has been renewed interest in non-primary forms of dystonia including the dystonia-plus syndromes and heredodegenerative disorders. These are caused by a variety of genetic mutations and their study has contributed to our understanding of the neuronal dysfunction that leads to dystonia These findings have reinforced themes identified from study of primary dystonia including abnormal dopaminergic signalling, cellular trafficking and mitochondrial function. In this review we highlight recent advances in the understanding of the dystonia-plus syndromes and heredodegenerative dystonias.
    Current Neuropharmacology 01/2013; 11(1):30-40. DOI:10.2174/157015913804999432 · 3.05 Impact Factor
Show more